Modern Healthspan: CRISPR Therapy: Silencing PCSK9 Gene for Heart Health #shorts
Peer-Reviewed Research
Key Takeaways
- CRISPR-based PCSK9 therapy is in human trials for cardiovascular disease prevention.
- This approach epigenetically silences PCSK9 rather than blocking the protein like current drugs.
- Potential for one-time treatment instead of daily PCSK9 inhibitor medications.
- Phase 1 trial focuses on safety – effectiveness and durability still unknown.
Bottom Line
Watch for updates on this CRISPR therapy if you’re interested in long-term heart health solutions beyond daily medications. Ask your doctor about current PCSK9 inhibitor options if LDL cholesterol is a concern.
Explore More
- Modern Healthspan’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
- Matt Kaeberlein: A calcium score is not a good screening tool
- Michael Greger: Friday Favorites: Dietary Approach to Naturally Treating Menopause Symptoms
- Mark Hyman: Function is shifting how modern medicine looks at women’s health.
- Michael Greger: How Ultra-Processed Foods Could Cause Disease: Loss of Phytonutrients
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network